Zoetis Inc. (ZTS) Current Ratio
- Current ratio · latest quarter: Value 3.08×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 3.08× | Current assets / current liabilities. $6.36B ÷ $2.06B ≈ 3.08× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 6.36B USD | Assets, Current |
| Current obligations | 2.06B USD | Liabilities, Current |
| Cash and equivalents | 1.48B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 1.57B USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 2.57B USD | Inventory, Net |
| Payables | 452.00M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.36B | $2.06B | $1.48B | (m) | $1.57B | $2.57B | $452.00M | (m) | 3.08× |
| 2026-03-31 | $6.47B | $2.05B | $1.94B | (m) | $1.51B | $2.55B | $507.00M | (m) | 3.15× |
| 2025-12-31 | $6.77B | $2.17B | $2.45B | (m) | $1.41B | $2.46B | $445.00M | (m) | 3.12× |
| 2025-09-30 | $6.58B | $1.81B | $2.08B | (m) | $1.54B | $2.46B | $410.00M | $0.00 | 3.64× |
| 2025-06-30 | $5.92B | $3.37B | $1.44B | (m) | $1.54B | $2.44B | $508.00M | $1.35B | 1.76× |
| 2025-03-31 | $5.88B | $3.38B | $1.72B | (m) | $1.36B | $2.37B | $420.00M | $1.35B | 1.74× |
| 2024-12-31 | $5.99B | $3.41B | (m) | (m) | $1.32B | $2.31B | $433.00M | $1.35B | 1.75× |
| 2024-09-30 | $6.28B | $1.70B | $1.71B | (m) | $1.41B | $2.42B | $404.00M | (m) | 3.69× |
| 2024-06-30 | $6.20B | $1.80B | $1.57B | (m) | $1.38B | $2.45B | $420.00M | (m) | 3.45× |
| 2024-03-31 | $6.36B | $1.91B | $1.98B | (m) | $1.29B | $2.65B | $405.00M | (m) | 3.33× |
| 2023-12-31 | $6.34B | $1.89B | (m) | (m) | $1.30B | $2.56B | $411.00M | $0.00 | 3.36× |
| 2023-09-30 | $6.22B | $1.61B | $1.75B | (m) | $1.26B | $2.74B | $388.00M | $0.00 | 3.87× |
| 2023-06-30 | $6.18B | $1.77B | $1.72B | (m) | $1.32B | $2.70B | $464.00M | $0.00 | 3.50× |
| 2023-03-31 | $6.27B | $1.92B | $2.11B | (m) | $1.19B | $2.56B | $424.00M | $0.00 | 3.27× |
| 2022-12-31 | $7.51B | $3.17B | (m) | (m) | $1.22B | $2.35B | $405.00M | $1.35B | 2.37× |
| 2022-09-30 | $6.55B | $2.88B | $2.51B | (m) | $1.19B | $2.30B | $373.00M | $1.35B | 2.27× |
| 2022-06-30 | $6.65B | $3.05B | $2.65B | (m) | $1.29B | $2.21B | $430.00M | $1.35B | 2.18× |
| 2022-03-31 | $6.84B | $3.03B | $3.13B | (m) | $1.22B | $2.06B | $402.00M | $1.35B | 2.25× |
| 2021-12-31 | $6.93B | $1.80B | (m) | (m) | $1.13B | $1.92B | $436.00M | $0.00 | 3.86× |
| 2021-09-30 | $6.68B | $1.47B | $3.27B | (m) | $1.15B | $1.88B | $387.00M | $0.00 | 4.54× |
| 2021-06-30 | $7.05B | $2.09B | $3.66B | (m) | $1.17B | $1.80B | $369.00M | $600.00M | 3.37× |
| 2021-03-31 | $6.79B | $2.07B | $3.60B | (m) | $1.13B | $1.70B | $346.00M | $600.00M | 3.29× |
| 2020-12-31 | $6.61B | $2.17B | (m) | (m) | $1.01B | $1.63B | $457.00M | $600.00M | 3.05× |
| 2020-09-30 | $6.76B | $2.40B | $3.65B | (m) | $1.01B | $1.63B | $357.00M | $1.10B | 2.82× |
| 2020-06-30 | $6.29B | $1.81B | $3.35B | (m) | $984.00M | $1.58B | $335.00M | $500.00M | 3.47× |
| 2020-03-31 | $4.77B | $1.72B | $1.95B | (m) | $965.00M | $1.48B | $265.00M | $500.00M | 2.77× |
| 2019-12-31 | $4.75B | $1.81B | (m) | (m) | $1.09B | $1.41B | $301.00M | $500.00M | 2.63× |
| 2019-09-30 | $4.62B | $1.05B | $1.81B | (m) | $1.03B | $1.44B | $284.00M | (m) | 4.39× |
| 2019-06-30 | $4.48B | $1.07B | $1.75B | (m) | $994.00M | $1.40B | $290.00M | (m) | 4.17× |
| 2019-03-31 | $4.38B | $1.08B | $1.73B | (m) | $970.00M | $1.36B | $235.00M | (m) | 4.05× |
| 2018-12-31 | $4.40B | $1.22B | (m) | (m) | $1.04B | $1.39B | $313.00M | $0.00 | 3.60× |
| 2018-09-30 | $4.08B | $1.00B | $1.29B | (m) | $929.00M | $1.44B | $238.00M | (m) | 4.06× |
| 2018-06-30 | $4.24B | $967.00M | $1.56B | (m) | $973.00M | $1.42B | $230.00M | (m) | 4.38× |
| 2018-03-31 | $4.27B | $1.00B | $1.65B | (m) | $943.00M | $1.44B | $217.00M | (m) | 4.27× |
| 2017-12-31 | $4.22B | $1.09B | (m) | (m) | $998.00M | $1.43B | $261.00M | (m) | 3.85× |
| 2017-10-01 | $4.89B | $1.75B | $1.98B | (m) | $1.01B | $1.49B | $213.00M | $750.00M | 2.80× |
| 2017-07-02 | $3.58B | $1.78B | $705.00M | (m) | $975.00M | $1.50B | $199.00M | $750.00M | 2.01× |
| 2017-04-02 | $3.38B | $1.73B | $629.00M | (m) | $954.00M | $1.53B | $231.00M | $750.00M | 1.96× |
| 2016-12-31 | $3.39B | $1.12B | $727.00M | (m) | $913.00M | $1.50B | $265.00M | $0.00 | 3.03× |
| 2016-10-02 | $3.36B | $1.04B | $651.00M | (m) | $915.00M | $1.56B | $241.00M | $0.00 | 3.24× |
| 2016-07-03 | $3.33B | $1.04B | $658.00M | (m) | $888.00M | $1.52B | $224.00M | $0.00 | 3.20× |
| 2016-04-03 | $3.31B | $1.16B | $675.00M | (m) | $908.00M | $1.46B | $210.00M | $0.00 | 2.84× |
| 2015-12-31 | $3.83B | $1.78B | $1.15B | (m) | $937.00M | $1.47B | $293.00M | $400.00M | 2.15× |
| 2015-09-27 | $3.45B | $1.66B | $592.00M | (m) | $1.04B | $1.40B | $306.00M | $400.00M | 2.08× |
| 2015-06-28 | $3.32B | $1.57B | $544.00M | (m) | $993.00M | $1.42B | $278.00M | $400.00M | 2.11× |
| 2015-03-29 | $3.11B | $1.37B | $559.00M | (m) | $905.00M | $1.35B | $256.00M | $400.00M | 2.27× |
| 2014-12-31 | $3.46B | $1.09B | $882.00M | (m) | $980.00M | $1.29B | $290.00M | $0.00 | 3.19× |
| 2014-09-28 | $3.35B | $998.00M | $598.00M | (m) | $1.06B | $1.39B | $259.00M | (m) | 3.36× |
| 2014-06-29 | $3.33B | $1.06B | $578.00M | (m) | $1.10B | $1.34B | $337.00M | (m) | 3.14× |
| 2014-03-30 | $3.22B | $1.13B | $506.00M | (m) | $1.10B | $1.32B | $363.00M | (m) | 2.86× |
| 2013-12-31 | $3.36B | $1.42B | $610.00M | (m) | $1.14B | $1.29B | $506.00M | (m) | 2.37× |
| 2013-09-29 | $3.08B | $1.31B | $389.00M | (m) | $1.11B | $1.29B | $482.00M | (m) | 2.36× |
| 2013-06-30 | $3.08B | $1.32B | $369.00M | (m) | $1.14B | $1.26B | $587.00M | (m) | 2.33× |
| 2013-03-31 | $2.94B | $1.29B | $468.00M | (m) | $861.00M | $1.12B | $275.00M | (m) | 2.29× |
| 2012-12-31 | $2.86B | $1.12B | $317.00M | (m) | $900.00M | $1.34B | $319.00M | (m) | 2.55× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |